Could growth factors help repair the liver in cirrhosis?
NCT ID NCT07002827
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tests whether giving a combination of two growth factors (G-CSF and darbepoetin) in single or repeated cycles can improve immune function in people with early decompensated cirrhosis. Sixty participants will be randomly assigned to receive either the growth factor combination or standard medical care. The main goal is to see changes in immune cell activity over six months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Granulocyte colony stimulating factor (G-CSF) and darbepoetin
What this could lead to
If successful, this could point toward a new way to boost the immune system and slow liver disease progression in people with early decompensated cirrhosis.
What could go wrong
This is a small pilot study with only 60 participants, so results may not apply to everyone. The treatment involves growth factors, which can cause side effects like bone pain or allergic reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DECOMPENSATED LIVER CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Liver & Biliary Sciences (ILBS)
RECRUITINGNew Delhi, National Capital Territory of Delhi, 110070, India
Contact Phone: •••-•••-•••• Email: •••••@•••••